CLINICAL ENCOUNTERS
DIABETIC RETINOPATHY
|
Question
[CLICK ON ANY CHOICE TO KNOW THE RIGHT ANSWER]
|
What are the anti-VEGF regimens used in the research in this journal?
|
|
Triamcinolone acetonide, Bevacizumab, or Ranibizumab
|
|
|
Lucentis, Triamcinolone acetonide, atau Bevacizumab
|
|
|
Bevacizumab, Ranibizumab, or Aflibercept
|
|
|
Lucentis, Triamcinolone acetonide, atau Eylia
|
Explanation:
Detailed explanation-1: -Ranibizumab is a small recombinant, humanized, monoclonal antibody that neutralizes all forms of vascular endothelial growth factor (VEGF) A, 1 whereas aflibercept is a larger recombinant fusion protein that neutralizes all VEGF-A isoforms as well as VEGF-B and placental growth factor.
Detailed explanation-2: -In the United States, intravitreal anti-VEGF agents approved by the Food and Drug Administration include not only ranibizumab, aflibercept, brolucizumab and faricimab, but also recently approved biosimilar anti-VEGF agents. All of these anti-VEGFs are biotechnology-derived protein products, classified as biologics.
There is 1 question to complete.